Disease

Subarachnoid Hemorrhage

Late-stage therapeutic developmentEmerging research

MeSHSubarachnoid Hemorrhage

Publications

Clinical trials

Related conditions

Associated genes

Related proteins

2023

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.

Research2023-05-22Stroke

Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

Research2021-09-03The Lancet. Neurology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate

Key developments

3 clinical trials expected to report results, the earliest in Q4 2027.

Upcoming Milestones

Major developments

Upcoming trial readoutHigh impact

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)

Results expected Q2 20292026-09-11

Major clinical milestoneImportant

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-2 (IRIS-2)

Primary completion2026-09-18

Clinical Milestones8View

Results expected 3

2026-09-21Development and Validation of an Adaptive Neurofeedback Interface Using Transcranial Magnetic Stimulation to Modulate Cortical ExcitabilityResults expected Q4 2027
2026-09-11Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)Results expected Q2 2029
2026-07-07An Open-label Extension Study Evaluating the Safety of Zagociguat in Participants With MELAS Who Completed TIS6463-203Results expected Q3 2028

Recently completed 2

Other updates 3

Activity timeline8

2027-12-31ClinicalHigh Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: Paediatric Arteriopathy Steroid Aspirin (PASTA) Project. A Multicentre Randomized Trial.Withdrawn
2026-10-01ClinicalA Phase 3 Study to Evaluate the Efficacy and Safety of 3K3A-APC in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy, or Both in Subjects with Moderate to Severe Acute Ischemic StrokeWithdrawn
2026-09-30ClinicalA Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic StrokePrimary completion
2026-09-21ClinicalDevelopment and Validation of an Adaptive Neurofeedback Interface Using Transcranial Magnetic Stimulation to Modulate Cortical ExcitabilityResults expected Q4 2027
2026-09-18ClinicalEfficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-2 (IRIS-2)Primary completion
2026-09-11ClinicalComparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)Results expected Q2 2029
2026-07-07ClinicalAn Open-label Extension Study Evaluating the Safety of Zagociguat in Participants With MELAS Who Completed TIS6463-203Results expected Q3 2028
2026-03-01ClinicalEfficacy of Minocycline in Improving Neurological Outcomes of Patients Who Undergo Endovascular Revascularization for Acute Ischemic StrokeWithdrawn

Clinical trials

14 sponsors · 2 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Patients With Acute Ischemic Strokes With Large Infarct: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial (MIRACLE)

Phase 3 · Active, not recruiting · Wan-Jin Chen

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)

Phase 4 · Active, not recruiting · Seoul National University Hospital

Phase 3 · Active, not recruiting · Capital Medical University

Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Phase 3 · Completed · H. Lundbeck A/S

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)

Phase 3 · Completed · Boehringer Ingelheim

Recently completed

Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Phase 3 · Completed · H. Lundbeck A/S

Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon Carotid Intima-media Complex Thickness in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Phase 3 · Completed · Boehringer Ingelheim

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily

Phase 3 · Completed · Boehringer Ingelheim

EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study

Phase 4 · Completed · Boehringer Ingelheim

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time

2021–2023

Most influential

Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

The Lancet. Neurology · 2021 · 5,279 cites

2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.

Stroke · 2023 · 683 cites

Recent publications

2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.

Stroke · 2023 · 683 cites

Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

The Lancet. Neurology · 2021 · 5,279 cites

Major themes3

Global Burden of Disease1
Stroke1
Subarachnoid Hemorrhage1

Leading journals2

Stroke1
The Lancet. Neurology1

Leading researchers8

Amin-Hanjani S1
Chou SH-Y1
Cruz-Flores S1
Dangayach NS1
Derdeyn CP1
Du R1
Hänggi D1
Hetts SW1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

SOCS60.33 NCKAP50.33 TAFA50.32 GNA140.32 HMCN10.32 ZNF5360.32 NAALADL20.32 PPP1R170.31 SH3GL20.31 CCDC1920.31 RNF2170.31 SEMA5A0.31

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Claudin-18via CLDN180.22

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Stroke2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.

Identifiers

MeSHSubarachnoid Hemorrhage

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.